2012-11-15T12:51:34-06:00 2011-12-31 410746749 CLIFTONLARSONALLEN LLP 4250 N FAIRFAX DRIVE SUITE 1020 ARLINGTON VA 22203 990 2011-01-01 521224577 BIOTECHNOLOGY INDUSTRY ORGANIZATION BIOT 2029629200 1201 MARYLAND AVE SW NO 900 WASHINGTON DC 20024 JOANNE M DUNCAN 2029629200 2012-11-15 1 KAREN GRIES P00078514 5712279500 2011 2016-02-24 21:20:13Z JAMES C GREENWOOD 1201 MARYLAND AVE SW NO 900 WASHINGTON DC 20024 77123142 0 X WWW.BIO.ORG X 1993 DC BIOTECHNOLOGY RESEARCHERS EXPAND THE BOUNDARIES OF SCIENCE TO BENEFIT MANKIND BY PROVIDING BETTER HEATHCARE, ENHANCED AGRICULTURE, AND A CLEANER AND SAFER ENVIRONMENT. THE MISSION OF BIO IS TO BE THE CHAMPION OF BIOTECHNOLOGY AND THE ADVOCATE FOR ITS MEMBER ORGANIZATIONS - BOTH LARGE AND SMALL. 116 116 184 196 333346 0 0 0 57498909 59284196 3478235 1994532 42100 3900 61019244 61282628 0 0 0 0 23396161 25311029 0 0 0 35354014 35650393 58750175 60961422 2269069 321206 65414013 65857637 26464995 27777267 38949018 38080370 X THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) REPRESENTS MORE THAN 1,100 COMPANIES AND ORGANIZATIONS IN WASHINGTON DC, STATE CAPITALS, AND INTERNATIONAL FORA. BIOTECHNOLOGY INDUSTRY ORGANIZATION IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. OUR MEMBERS REPRESENT COMPANIES OFFERING A SPECTRUM OF BIOTECHNOLOGY APPLICATIONS ACROSS MAJOR SECTORS OF THE ECONOMY. BIOTECHNOLOGY INDUSTRY ORGANIZATION MEMBERS ALSO INCLUDE UNIVERSITIES, NONPROFITS, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT PLAY AN IMPORTANT ROLE IN THE FUTURE OF THE LIFE SCIENCES. BIOTECHNOLOGY INDUSTRY ORGANIZATION'S ACTIVITIES ARE BROKEN DOWN INTO TWO PROGRAMS - ADVOCACY AND SERVICES. 0 0 ADVOCACYBIO'S ADVOCACY EFFORTS REFLECT THE PRIORITIES IDENTIFIED BY THE BIO BOARD OF DIRECTORS AND THE FOUR SECTION GOVERNING BOARDS.THE BOARD OF DIRECTORS FOCUSES ON ISSUES OF IMPORTANCE TO ALL BIO MEMBERS, REGARDLESS OF THEIR SIZE OR TECHNOLOGY. THESE CROSS-CUTTING ADVOCACY ACCOMPLISHMENTS IN 2011 ARE LISTED BELOW. - SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY.- FOSTERED A DIALOGUE ABOUT ETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY.- PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH.- EXPANDED OUTREACH TO FOREIGN GOVERNMENTS AND ENTITIES TO EDUCATE ON POLICY ISSUES OF IMPORTANT TO THE BIOTECHNOLOGY INDUSTRY AND TO IMPROVE THE INVESTMENT AND REGULATORY CLIMATE FOR BIOTECH PRODUCTS.THE EMERGING COMPANIES SECTION ADVOCATES FOR POLICIES SUPPORTIVE OF SMALL INNOVATIVE COMPANIES IN AREAS SUCH AS TAX POLICY, FINANCIAL REPORTING AND ACCOUNTING LAW AND REGULATIONS, AND FEDERAL GRANTS. THE EMERGING COMPANIES SECTION'S 2011 ADVOCACY ACCOMPLISHMENTS ARE LISTED BELOW.- ADVANCED THE INTEREST OF EMERGING COMPANIES IN CAPITAL FORMATION AND FINANCIAL SERVICES POLICY.- INCREASED OPPORTUNITIES FOR SMALL COMPANIES TO RECEIVE FEDERAL GRANTS.- ADVOCATED FOR TAX POLICIES SUPPORTING INNOVATIVE EMERGING COMPANIES.- ADVOCATED FOR THE REMOVAL OF BURDENSOME FINANCIAL REPORTING REGULATIONS.- INFLUENCED HEALTH CARE POLICY TO REFLECT THE CONCERNS OF SMALL BIOTECHNOLOGY COMPANIES.THE FOOD & AGRICULTURE SECTION FOCUSES ON MAINTAINING A SCIENCE-BASED REGULATORY ENVIRONMENT FOR BIOTECH CROPS AND EMERGING PRODUCTS, SUCH AS PLANT- AND ANIMAL-MADE PHARMACEUTICALS AND FEEDSTOCKS FOR BIOFUELS. SOME OF THE FOOD AND AGRICULTURE SECTION'S 2011 ADVOCACY ACCOMPLISHMENTS ARE LISTED BELOW. - MOUNTED AN INITIATIVE, IN CONJUNCTION WITH ACADEMIC SCIENTISTS, TO OPPOSE EPA'S PROPOSED DATA REQUIREMENTS RULE AND CONVINCE EPA OF ITS DETRIMENTAL IMPACTS ON BIOTECHNOLOGY INNOVATION. - DEFENDED SCIENCE-BASED REVIEW OF GENETICALLY-ENGINEERED ANIMAL AGAINST LEGISLATIVE CHALLENGES IN APPROPRIATIONS PROCESS AND IN OTHER LEGISLATIVE AND REGULATORY VENUES, IN COORDINATION WITH ALLIED ANIMAL AGRICULTURE ORGANIZATIONS. - CONTINUED EDUCATION OF MEDIA AND POLICYMAKERS ON THE IMPORTANCE OF ANIMAL BIOTECHNOLOGY TO ENHANCE HUMAN AND ANIMAL HEALTH APPLICATIONS, FOOD PRODUCTION AND ENVIRONMENTAL SUSTAINABILITY; REVISED AND RE-PRINTED BIO'S REPORT, GENETICALLY ENGINEERED ANIMALS AND PUBLIC HEALTH, TO USE AS A HARD COPY AND WEB-BASED RESOURCE. - FOSTERED CONGRESSIONAL SUPPORT FOR THE FOOD AND AGRICULTURE SECTION'S KEY FEDERAL SPENDING PRIORITIES, SUCH AS FUNDING FOR APHIS-BRS, USDA'S OFFICE OF GENERAL COUNSEL, AGRICULTURAL ENERGY PRIORITIES, AGRICULTURAL RESEARCH PRIORITIES, FOOD SAFETY INSPECTION SERVICE, AND ANIMAL BIOTECHNOLOGY. - MITIGATED ATTACKS FROM ANTI-BIOTECH GROUPS WITH PROACTIVE WEB-BASED BENEFITS MESSAGING AND MEDIA OUTREACH, AS WELL AS EMPHASIZING THE IMPORTANCE OF TECHNOLOGY TO PRODUCTION AGRICULTURE AND MAINTAINING A RISK-BASED APPROACH TO FOOD LABELING POLICY.THE HEALTH SECTION DRIVES ADVOCACY TO ENSURE THAT PATIENTS HAVE ACCESS TO THE FRUITS OF BIOTECH RESEARCH, WHILE THE MARKETPLACE REWARDS THAT DRIVE CONTINUED INNOVATION ARE MAINTAINED. BELOW ARE THE HEALTH SECTION'S 2011 ACCOMPLISHMENTS.- INFLUENCED IMPROVEMENTS TO THE U.S. FOOD AND DRUG ADMINISTRATION'S (FDA'S) PROCESS FOR HUMAN DRUG REVIEW.- ENHANCED PATIENT ACCESS TO INNOVATIVE THERAPIES.- ADVOCATED FOR BIOSIMILARS POLICIES THAT PROTECT PATIENT SAFETY AND PROMOTE BIOMEDICAL INNOVATION.- PROMOTED DEVELOPMENT AND USE OF RESEARCH TOOLS, MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES. - ADVOCATED FOR POLICIES THAT FOSTER VACCINE INNOVATION AND PROMOTE PANDEMIC AND BIO-DEFENSE PREPAREDNESS.- INFLUENCED IMPROVEMENTS TO THE INTERNATIONAL ENVIRONMENT FOR BIOMEDICAL INNOVATION.THE INDUSTRIAL & ENVIRONMENTAL SECTION ADVOCATES FOR INCENTIVES THAT HELP CREATE MARKET DEMAND FOR CUTTING-EDGE CONSUMER PRODUCTS SUCH AS PLANT-BASED PLASTICS AND RENEWABLE FUELS AND CHEMICALS. BELOW ARE THE INDUSTRIAL & ENVIRONMENTAL SECTION'S 2011 ADVOCACY ACCOMPLISHMENTS.RENEWABLE FUEL STANDARD- SUCCESSFULLY ADVOCATED FOR AGGRESSIVE CELLULOSIC GALLON REQUIREMENTS UNDER EPA'S FINAL 2012 RFS RULE.TAX- SUCCESSFULLY ADVOCATED FOR THE INTRODUCTION OF SEVERAL FAVORABLE PIECES OF TAX LEGISLATION RELATING TO ALGAL, CELLULOSIC AND OTHER ADVANCED BIOFUELS.MILITARY USE- SECURED SUPPORT FOR $510 MILLION MULTI-AGENCY PLAN TO ACCELERATE COMMERCIALIZATION OF ADVANCED DROP-IN BIOFUELS FOR MILITARY USE.FARM BILL- SECURED STRONG ENERGY TITLE IN FARM BILL PROPOSALS IN CONGRESS. SYNTHETIC BIOLOGY- ADVOCATED REGARDING THE PROPER REGULATORY APPROACH IN THE EMERGING FIELD OF SYNTHETIC BIOLOGY.BIOBASED PRODUCTS & RENEWABLE SPECIALTY CHEMICALS- ADVOCATED FOR THE CERTIFICATION PROCESS FOR THE VOLUNTARY LABELING PROGRAM IN USDA'S BIOPREFERRED PROGRAM.- ADVOCATED FOR A PRODUCTION TAX CREDIT FRAMEWORK IN CONGRESS.CONFERENCES- BIO HELD TWO INDUSTRIAL BIOTECH CONFERENCES IN 2011-THE BIO WORLD CONGRESS ON INDUSTRIAL BIOTECHNOLOGY AND BIOPROCESSING AND THE BIO PACIFIC RIM SUMMIT ON INDUSTRIAL BIOTECHNOLOGY AND BIOENERGY. SERVICESBIO'S SERVICES INCLUDE CONFERENCES AND ACTIVITIES THAT BRING TOGETHER INDUSTRY PARTNERS AND INVESTORS FOR EVENTS RANGING FROM THE BIO INTERNATIONAL CONVENTION TO PROFESSIONAL DEVELOPMENT CONFERENCES FOR HUMAN RESOURCES AND BUSINESS DEVELOPMENT EXECUTIVES. BIO INTERNATIONAL CONVENTION - THE 2011 BIO INTERNATIONAL CONVENTION WAS HELD IN WASHINGTON, D.C., ON JUNE 27-30, 2011. THE EVENT ATTRACTED 15,626 ATTENDEES FROM 65 COUNTRIES, AND 48 U.S. STATES, INCLUDING 400 MEMBERS OF THE MEDIA. THE NET INCOME FROM THE CONVENTION SUPPORTS OUR ADVOCACY, PUBLIC OUTREACH, AND OTHER MEMBER SERVICE ACTIVITIES. 2011 BIO PARTICIPANTS INCLUDED 11 U.S. GOVERNORS, 75 HIGH-LEVEL PUBLIC OFFICIALS, AND LEADERS FROM U.S. CONGRESSIONAL STAFF AND REGULATORY AGENCIES.THE CONVENTION CONTINUED TO DRAW OVER 1/3 (33%+) OF THE ATTENDANCE FROM COUNTRIES OUTSIDE THE U.S.; WHICH INCLUDES MORE THAN 100 INTERNATIONAL PUBLIC OFFICIALS FROM 24 COUNTRIES, INCLUDING MINISTERS OF SCIENCE, AGRICULTURE, AND TECHNOLOGY AND AMBASSADORS FROM COUNTRIES SUCH AS BELGIUM, CANADA, DENMARK, HUNGARY, IRELAND, ISRAEL, MALAYSIA, NETHERLANDS, NEW ZEALAND, RUSSIAN EMBASSY AND SWITZERLAND.THE KEY ELEMENTS OF THE BIO INTERNATIONAL CONVENTION WERE:- EDUCATIONAL PROGRAMMING THAT INCLUDED 4 DAYS OF 125 BREAKOUT SESSIONS, 15 EDUCATIONAL TRACKS, MORE THAN 800 SPEAKERS, 2 KEYNOTE SESSIONS, AND 6 SUPER SESSIONS.- THE BIO BUSINESS FORUM, WHICH PROVIDED AN OPPORTUNITY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, ACADEMIC RESEARCH INSTITUTIONS AND INVESTORS FROM AROUND THE WORLD TO SCHEDULE ONE-ON-ONE MEETINGS AND DISCUSS POTENTIAL BUSINESS OPPORTUNITIES; IT HOSTED A RECORD NUMBER OF 21,183 PARTNERING MEETINGS BETWEEN 2,410 COMPANIES AND 157 COMPANY PRESENTATIONS SCHEDULED DURING THE CONVENTION.- THE BIO EXHIBITION HOSTED APPROXIMATELY 1,800 EXHIBITORS WITH 180,000 NET SQUARE FEET OF EXHIBIT SPACE. ATTENDEES MINGLED AMONG THE 61 STATE, COUNTRY AND REGIONAL PAVILIONS AND THE 6 PRODUCT FOCUS ZONES.- PROFESSIONAL NETWORKING TOOK PLACE THROUGHOUT THE CONVENTION DURING 3 LARGE GENERAL EVENTS, AS WELL AS NUMEROUS SMALLER RECEPTIONS. CAPITAL FORMATION & BUSINESS DEVELOPMENT - THROUGH A PORTFOLIO OF EVENTS, BIO SUPPORTS THE CAPITAL FORMATION AND BUSINESS DEVELOPMENT NEEDS OF HUNDREDS OF SMALL, INNOVATIVE COMPANIES THAT FORM THE BASIS OF THE BIOTECHNOLOGY INDUSTRY. THESE PROGRAMS FACILITATE CRITICAL CAPITAL FORMATION AND PARTNERSHIPS, AND PROVIDE PROFESSIONAL SERVICES. THROUGHOUT THE YEAR, BIO HOSTS OR CO-HOSTS 9 NATIONAL AND INTERNATIONAL CONFERENCES THAT PROVIDE VENUES FOR MEMBER AND NON-MEMBER COMPANIES TO PRESENT NEW DATA, MEET AND PARTNER WITH FELLOW BIOTECH COMPANIES, AND ATTRACT FUNDING FROM INVESTORS AND OTHER ORGANIZATIONS. THESE 2011 CONFERENCES SERVED MORE THAN 12,000 MEMBER AND NON-MEMBER ATTENDEES, AND INCLUDED MORE THAN 30,000 PARTNERING MEETINGS AND 950 COMPANY PRESENTATIONS OVER 10 DAYS OF OFFICIAL PROGRAMMING. THE 2011 U.S. PROGRAM INCLUDED: - BIO CEO & INVESTOR CONFERENCE, NEW YORK CITY, NY- BIO-WINDHOVER, NEW YORK CITY, NY, - BUSINESS FORUM AT THE BIO INTERNATIONAL CONVENTION, WASHINGTON, D.C.- BIO GLOBAL HEALTH CONFERENCE, WASHINGTON, D.C.- BIO INVESTOR FORUM, SAN FRANCISCO, CABIO ALSO ORGANIZES, HOSTS, OR ASSISTS WITH HOSTING, FIVE OF THE LARGEST BIOTECH MEETINGS OUTSIDE OF THE U.S.; THE 2011 THE PROGRAM INCLUDED:- BIO-ASIA, TOKYO, JAPAN- BIO-EUROPE SPRING- BIO INDIA, HYDERABAD, INDIA, - BIO CHINA, CHINA- BIO-EUROPE FALL, MUNICH, GERMANYIN ADDITION, IN 2011, BIO PROVIDED COST-EFFECTIVE EDUCATIONAL PROGRAMS TO HELP EXECUTIVES FROM SMALL COMPANIES. THESE WORKSHOPS, FOCUSED ON EXECUTIVE PRESENTATION SKILLS AND BASIC AND ADVANCED BUSINESS DEVELOPMENT SKILLS, WERE HELD THROUGHOUT THE YEAR IN VARIOUS LOCATIONS AROUND THE U.S. AND GERMANY. 0 0 1 1 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 180 0 184 1 1 1 1 IN 0 0 0 0 X 116 116 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X JOANNE M DUNCAN 2029629200 1201 MARYLAND AVE SW STE 900 WASHINGTON DC 20024 ATWOOD BRIAN 2.00 X 0 0 0 BEALL ROBERT 2.00 X 0 0 0 BEEMAN DONALD 2.00 X 0 0 0 BEER MARC 2.00 X 0 0 0 BERVEN DOUG 2.00 X 0 0 0 BIENAIME JEAN-JACQUES 2.00 X 0 0 0 BOGER JOSHUA 2.00 X 0 0 0 BORISY ALEXIS 2.00 X 0 0 0 BORMANN BJ 2.00 X 0 0 0 CLARK IAN 2.00 X 0 0 0 COHEN BRUCE 2.00 X 0 0 0 COHEN RON 2.00 X 0 0 0 COLES N 2.00 X 0 0 0 CONWAY ROBERT 2.00 X 0 0 0 CROWLEY JOHN 2.00 X 0 0 0 DE RUITER TJERK 2.00 X 0 0 0 DEBETHIZY J DONALD 2.00 X 0 0 0 DOERFLER DOUGLAS 2.00 X 0 0 0 DUNCAN GREG 2.00 X 0 0 0 DUNSIRE DEBORAH 2.00 X 0 0 0 EGGERT CHARLES 2.00 X 0 0 0 ELLERBUSCH SUSAN 2.00 X 0 0 0 ENO RICHARD 2.00 X 0 0 0 FERGUSON BRUCE 2.00 X 0 0 0 FISCHER PAUL 2.00 X 0 0 0 FLINT JERRY 2.00 X 0 0 0 FRITZ CAROLYN 2.00 X 0 0 0 GATTO STEPHEN 2.00 X 0 0 0 GERBERDING JULIE 2.00 X 0 0 0 GERMANO GENO 2.00 X 0 0 0 GIOVANNETTI GLEN 2.00 X 0 0 0 GOLD MITCHELL 2.00 X 0 0 0 GORMLEY GLENN 2.00 X 0 0 0 GOWEN MAXINE 2.00 X 0 0 0 GREENLEAF PETER 2.00 X 0 0 0 GRUBER PATRICK 2.00 X 0 0 0 GUTTERSON NEAL 2.00 X 0 0 0 HALE DAVID 2.00 X 0 0 0 HA-NGOC TUAN 2.00 X 0 0 0 HASTINGS PAUL 2.00 X 0 0 0 HATFIELD JEFFERY 2.00 X 0 0 0 HERNDON RUSSELL 2.00 X 0 0 0 HOLTZMAN STEVEN 2.00 X 0 0 0 HOPPENOT HERVE 2.00 X 0 0 0 HOYES JAMES 2.00 X 0 0 0 HUTTNER JACK 2.00 X 0 0 0 JUNIUS DANIEL 2.00 X 0 0 0 KARSEN PERRY 2.00 X 0 0 0 KING RACHEL 2.00 X 0 0 0 KOENIG SCOTT 2.00 X 0 0 0 KOSACZ BARBARA 2.00 X 0 0 0 KREMER MATTHIAS 2.00 X 0 0 0 KU KATHERINE 2.00 X 0 0 0 LEAHY EMER 2.00 X 0 0 0 LEFF JONATHAN 2.00 X 0 0 0 LEONARD JOHN 2.00 X 0 0 0 LESCHLY NICK 2.00 X 0 0 0 LEVINE JAMES 2.00 X 0 0 0 LUNDBERG JAN 2.00 X 0 0 0 MANUSO JAMES 2.00 X 0 0 0 MARAGANORE JOHN 2.00 X 0 0 0 MATHERS EDWARD 2.00 X 0 0 0 MATHERS THOMAS 2.00 X 0 0 0 MCCAULEY GORDON 2.00 X 0 0 0 MCHUGH JULIE 2.00 X 0 0 0 MEDFORD RUSSELL 2.00 X 0 0 0 MEEKER DAVID 2.00 X 0 0 0 MENTO STEVEN 2.00 X 0 0 0 MILANO VINCENT 2.00 X 0 0 0 MILLIGAN JOHN 2.00 X 0 0 0 MOCH KENNETH 2.00 X 0 0 0 MONROE ADAM 2.00 X 0 0 0 MYERS DAN 2.00 X 0 0 0 NICOLAIDES NICHOLAS 2.00 X 0 0 0 ORWIN JOHN 2.00 X 0 0 0 OSTROVE JEFFERY 2.00 X 0 0 0 PARKINSON ROBERT 2.00 X 0 0 0 PELTZ STUART 2.00 X 0 0 0 PERKINS ADELENE 2.00 X 0 0 0 PETERSON KRISTINE 2.00 X 0 0 0 POPS RICHARD 2.00 X 0 0 0 PRUZANSKI MARK 2.00 X 0 0 0 PYOTT DAVID 2.00 X 0 0 0 READNOUR ROBIN 2.00 X 0 0 0 ROBIN HOWARD 2.00 X 0 0 0 RODELL TIMOTHY 2.00 X 0 0 0 RYDER STEVEN 2.00 X 0 0 0 SANDS ARTHUR 2.00 X 0 0 0 SCHMIDT RALF-MICHAEL 2.00 X 0 0 0 SHAW ALAN 2.00 X 0 0 0 SHERWIN STEPHEN 2.00 X 0 0 0 SHURDUT BRADLEY 2.00 X 0 0 0 SIEGEL JAY 2.00 X 0 0 0 STANDLEE CHRISTOPHER 2.00 X 0 0 0 STEINER GERALD 2.00 X 0 0 0 STOTISH RONALD 2.00 X 0 0 0 STRAHLMAN ELLEN 2.00 X 0 0 0 SULLIVAN EDDIE 2.00 X 0 0 0 TANDA STEPHAN 2.00 X 0 0 0 TASSE DANIEL 2.00 X 0 0 0 THAKRAR ATUL 2.00 X 0 0 0 TURCK ROLAND 2.00 X 0 0 0 TUTTLE STEVEN 2.00 X 0 0 0 VAN BOKKENLEN GIL 2.00 X 0 0 0 VAN WART HAROLD 2.00 X 0 0 0 VERBRUGGEN MARC 2.00 X 0 0 0 WALBERT TIMOTHY 2.00 X 0 0 0 WELLS BARBARA 2.00 X 0 0 0 WOLFSON JONATHAN 2.00 X 0 0 0 WONG MARK 2.00 X 0 0 0 WYSE ROGER 2.00 X 0 0 0 XANTHOPOULO KLEANTHIS 2.00 X 0 0 0 ZAKES BRADFORD 2.00 X 0 0 0 ZERBE ROBERT 2.00 X 0 0 0 BONANNI FABRIZIO 2.00 X X 0 0 0 SKALETSKY MARK 2.00 X X 0 0 0 WATKINS H THOMAS 2.00 X X 0 0 0 GREENWOOD JAMES 50.00 X 2367875 0 102549 MURPHY EARLY LISA 50.00 X 289629 0 10271 JOANNE DUNCAN 50.00 X 34369 0 1850 WHITAKER A SCOTT 50.00 X 710480 0 53478 DILENGE THOMAS 50.00 X 380970 0 53769 EISENBERG ALAN 50.00 X 392298 0 54776 DEL MONTE BRENT 50.00 X 355037 0 43862 ERICKSON BRENT 50.00 X 392546 0 51522 JOSEPH JEFFREY 50.00 X 307255 0 50489 FINAN AMY 50.00 X 346142 0 44514 LYCETT ROBERTA 50.00 X 264984 0 49110 RADCLIFFE SARA 50.00 X 437828 0 44017 DARRAGH SEAN 50.00 X 261029 0 17296 DENNIS SANDRA 50.00 X 279312 0 45995 SAUER HANSJORG 50.00 X 270005 0 44041 MCHUGH PETER 50.00 X 234496 0 44861 FEISEE LILA 50.00 X 255566 0 53051 7579821 0 765451 67 0 1 0 FREEMAN COMPANIES 1600 VICEROY SUITE 100 DALLAS TX 75247 GENERAL CONTRACTOR: CONV/CONFERENCES 1324777 PROJECTION INC PO BOX 890472 CHARLOTTE NC 28289 VIDEO SERVICES: CONV/CONFERENCES 875577 VOLUME SERVICES AMERICA 111 WEST HARBOR DR SAN DIEGO CA 92101 CATERING SERVICES: INTN'L CONV 836267 RHODE PLANNING & MGMT SOLUTIONS 42 LADD ST SUITE 302 EAST GREENWICH RI 02818 TRANSPORTATION SERVICES: INTN'L CONV 818268 FIXATION MARKETING 4340 EAST-WEST HWY SUITE 200 BETHESDA MD 208144411 MARKETING: INTN'L CONVENTION 661363 78 CONFERENCE/MEETING REV 541800 33488589 33221422 267167 MEMBERSHIP DUES 900099 22173807 22173807 BUSINESS SOLUTIONS 900099 3555215 3555215 PUBLICATION ADVERTISIN 541800 66585 406 66179 59284196 1563571 1563571 16271475 15840514 430961 430961 430961 INTERNET REVENUES 900099 3900 3900 3900 61282628 55399535 333346 5549747 5956466 14267376 2067918 1997099 1022170 348999 70951 3147612 261808 4586188 230217 1865342 822172 3699419 895308 16635286 2949 1155732 1179139 103370 OUTREACH 513037 TAXES PAID 75547 EDUCATION 42957 BAD DEBT EXPENSE 14360 60961422 6979800 4459681 1805535 2602547 2907323 2383665 11797165 7764303 4852112 4032862 48535212 52118530 334031 260352 65414013 65857637 8055493 8591779 12037740 13043071 6371762 6142417 26464995 27777267 X 38949018 38080370 38949018 38080370 65414013 65857637 X 321206 -1189854 X 0 1 1 X 0 2500 2500 2500 1 FRIENDS OF SUSANA MENDOZA 2646 S SAWYER AVENUE CHICAGO IL 60623 870732736 2500 0 0 1 22173807 7990000 14386 8004386 7983000 21386 ORGANIZATIONS DIRECT AND INDIRECT POLITICAL CAMPAIGN ACTIVITIES: PART I-A, LINE 1: POLITICAL CAMPAIGN CONTRIBUTION 7882920 4567950 3314970 3914245 3196353 717892 4032862 CAPITAL LEASE OBLIGATION 182799 DEFERRED RENT 5959618 6142417 61282628 60961422 321206 -1204082 14228 -1189854 -868648 62540294 1519474 1519474 61020820 261808 261808 61282628 62204860 1505246 1505246 60699614 261808 261808 60961422 PART XI, LINE 8 - OTHER ADJUSTMENTS: CBI REVENUE 31,741. CBI LOBBYING FUND REVENUE 442,576. FOOD & AG INITIATIVES REVENUE 128,507. FOOD & AG INITIATIVES EXPENSES -132,791. CBI LOBBYING FUND EXPENSE -455,805. TOTAL TO SCHEDULE D, PART XI, LINE 8: 14,228. PART XII, LINE 2D - OTHER ADJUSTMENTS: CBI 31,741. CBI LOBBYING FUND 442,576. FOOD & AG INITIATIVES REVENUE 128,507. MEDICARE EXPENSES 916,650. PART XIII, LINE 2D - OTHER ADJUSTMENTS: FOOD & AG INITIATIVES EXPENSES 132,791. CBI LOBBYING FUND 455,805. MEDICARE EXPENSES 916,650. PART X, LINE 2: THE ORGANIZATION ADOPTED THE INCOME TAX STANDARD FOR UNCERTAIN TAX POSITIONS IN 2010. THE ORGANIZATION HAS EVALUATED ITS TAX POSITIONS FOR 2011 AND DETERMINED THAT ITS TAX POSITIONS ARE MORE-LIKELY-THAN-NOT TO BE SUSTAINED ON EXAMINATION. AS SUCH, THE 2011 FINANCIAL STATEMENTS ARE NOT REQUIRED AND THEREFORE DO NOT CONTAIN A FOOTNOTE RELATED TO UNCERTAIN TAX POSITIONS. EUROPE 0 1 PROGRAM SERVICES CONFERENCE 124582 SOUTH ASIA 0 3 PROGRAM SERVICES CONFERENCE 293466 EAST ASIA AND THE PACIFIC 0 2 PROGRAM SERVICES CONFERENCE 1798757 NORTH AMERICA 0 0 PROGRAM SERVICES CONFERENCE 921260 0 6 0 0 0 6 3138065 0 3138065 0 0 0 0 0 0 X X X 1 1 X X X X X 0 1 0 GREENWOOD JAMES 1000168 0 349200 0 1018507 0 28702 0 73847 0 2470424 0 1018507 0 MURPHY EARLY LISA 178434 0 111195 0 0 0 1923 0 8348 0 299900 0 0 0 WHITAKER A SCOTT 552980 0 157500 0 0 0 28702 0 24776 0 763958 0 0 0 DILENGE THOMAS 380970 0 0 0 0 0 28702 0 25067 0 434739 0 0 0 EISENBERG ALAN 392298 0 0 0 0 0 28702 0 26074 0 447074 0 0 0 DEL MONTE BRENT 355037 0 0 0 0 0 28702 0 15160 0 398899 0 0 0 ERICKSON BRENT 327546 0 65000 0 0 0 28702 0 22820 0 444068 0 0 0 JOSEPH JEFFREY 307255 0 0 0 0 0 25027 0 25462 0 357744 0 0 0 FINAN AMY 268142 0 78000 0 0 0 28586 0 15928 0 390656 0 0 0 LYCETT ROBERTA 264984 0 0 0 0 0 28702 0 20408 0 314094 0 0 0 RADCLIFFE SARA 340328 0 97500 0 0 0 28702 0 15315 0 481845 0 0 0 DARRAGH SEAN 166529 0 94500 0 0 0 2048 0 15248 0 278325 0 0 0 DENNIS SANDRA 267812 0 11500 0 0 0 28702 0 17293 0 325307 0 0 0 SAUER HANSJORG 250505 0 19500 0 0 0 26748 0 17293 0 314046 0 0 0 MCHUGH PETER 214996 0 19500 0 0 0 27579 0 17282 0 279357 0 0 0 FEISEE LILA 223350 0 32216 0 0 0 28367 0 24684 0 308617 0 0 0 PART I, LINE 1A JAMES GREENWOOD - FIRST CLASS TRAVEL - $13,619 - TRAVEL FOR COMPANIONS - $1,392 - HEALTH/SOCIAL CLUB DUES - $4,125 ALAN EISENBERG - HEALTH/SOCIAL CLUB DUES - $780 THE ABOVE ITEMS WERE NOT INCLUDED IN THE TAXABLE INCOME OF THE INDIVIDUAL. PART I, LINE 4B JAMES GREENWOOD 457(F) PLAN $1,018,507 FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS SHALL DESIGNATE, BY RESOLUTION AND WITH A QUORUM PRESENT, NOT MORE THAN NINETEEN (19) DIRECTORS OF THE BOARD TO ACT AS AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL CONSIST OF THE SEVEN (7) ELECTED OFFICERS OF THE ORGANIZATION (AS DEFINED IN ARTICLE VIII); THE IMMEDIATE PAST CHAIR OF THE ORGANIZATION; THE VICE CHAIRS OF EACH SECTION'S GOVERNING BOARD; AND THE BALANCE BEING AT-LARGE DIRECTORS FROM THE FULL BOARD. IF THE IMMEDIATE PAST CHAIR IS NO LONGER ELIGIBLE TO SERVE ON THE FULL BOARD, AN ADDITIONAL AT-LARGE DIRECTOR FROM THE FULL BOARD SHALL BE SELECTED FOR THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE, AND BE AUTHORIZED TO EXERCISE, ALL POWERS OF THE FULL BOARD, EXCEPT: (A) THE POWER TO ELECT OR REMOVE ELECTED OFFICERS OR DIRECTORS, TO CHANGE THE SIZE OF THE BOARD, TO CHANGE ELIGIBILITY, QUALIFICATIONS OR RIGHTS OF MEMBERSHIP, TO APPROVE THE FINANCIAL BUDGET FOR THE ORGANIZATION, OR TO MAKE DETERMINATIONS AS TO DIRECTOR AND OFFICER COMPENSATION, WHERE APPLICABLE; AND (B) THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 BASED ON RESPONSES TO A SURVEY DISTRIBUTED TO EACH MEMBER OF BIOS BOARD OF DIRECTORS, TWO MEMBERS - MAXINE GOWEN AND VINCENT MILANO - DISCLOSED A BUSINESS RELATIONSHIP WITH ANOTHER MEMBER OF THE BIO BOARD DURING 2011. IN BOTH CASES, THE BUSINESS RELATIONSHIP WAS IDENTIFIED AS A DIRECTOR BEING ON THE BOARD OF ANOTHER BIO MEMBER COMPANY THAT IS REPRESENTED ON BIOS BOARD. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE ORGANIZATION SHALL BE DIVIDED INTO FOUR CLASSES; CORE MEMBERS, ASSOCIATE MEMBERS, AFFILIATE MEMBERS, AND CENTER MEMBERS, DEFINED AS FOLLOWS: (A) CORE MEMBERS. ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PERCENTAGE OF WHOSE BUSINESS ACTIVITIES INVOLVE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR RELATED NEW TECHNOLOGIES, IS ELIGIBLE FOR MEMBERSHIP. CORE MEMBERS ARE THOSE ENTITIES THAT UTILIZE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR OTHER RELATED NEW TECHNOLOGIES IN RESEARCH, DEVELOPMENT, TESTING, MANUFACTURING, OR SALES OF PRODUCT OR INFORMATION, AS WELL AS OTHER FIRMS THE BOARD SO CHARACTERIZES AND PLACES IN THIS CATEGORY. CORE MEMBERS SHALL BE GROUPED IN THE FOLLOWING SUBCATEGORIES: (I) EMERGING COMPANIES, WHICH ARE FIRMS THAT EMPLOY LESS THAN 350 PERSONS AND THAT DO NOT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (II) ESTABLISHED FIRMS, WHICH ARE THOSE FIRMS THAT EMPLOY 350 OR MORE PERSONS OR THAT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; AND (III) LARGE FIRMS, WHICH ARE ESTABLISHED FIRMS THAT HAVE ANNUAL WORLDWIDE SALES OF BIOTECHNOLOGY PRODUCTS IN EXCESS OF $1.5 BILLION; AND (IV) NON-DOMESTIC COMPANIES, WHICH ARE CORE MEMBERS WITHOUT SIGNIFICANT OPERATIONS IN THE UNITED STATES OR SIGNIFICANT COLLABORATIONS WITH A U.S. ENTITY. (B) ASSOCIATE MEMBERS. ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PORTION OF WHOSE ACTIVITIES INVOLVE PROVIDING SERVICES OR PRODUCTS OF BENEFIT TO COMPANIES WHOSE PRINCIPAL BUSINESS IS BIOTECHNOLOGY, IS ELIGIBLE FOR ASSOCIATE MEMBERSHIP. ASSOCIATE MEMBERS ARE THOSE COMMERCIAL ENTITIES WHICH DO NOT NECESSARILY UTILIZE BIOTECHNOLOGY; E.G. TECHNICAL SUPPORT, EQUIPMENT, CONSTRUCTION, ACCOUNTING, AND LAW FIRMS THAT SERVICE THE BIOTECHNOLOGY INDUSTRY, AS WELL AS OTHER FIRMS THAT THE BOARD CHARACTERIZES AND PLACES IN THIS CATEGORY. (C) AFFILIATE MEMBERS. ANY GOVERNMENTAL OR NONPROFIT ENTITY OR COUNTRY, STATE OR REGIONAL INDUSTRY, TRADE OR PROFESSIONAL ASSOCIATION WITH AN INTEREST IN, OR A MANDATE TO PROMOTE THE DEVELOPMENT OF, BIOTECHNOLOGY IS ELIGIBLE FOR AFFILIATE MEMBERSHIP. THERE SHALL BE NO SIZE TESTS APPLIED TO AFFILIATE MEMBER APPLICANTS. (D) CENTER MEMBERS. ANY INSTITUTION, NOT GENERALLY ELIGIBLE FOR CORE MEMBERSHIP THAT IS SPONSORED BY A STATE, REGION OR ACADEMIC INSTITUTION AND WORKS IN SUPPORT OF COMMERCIAL BIOTECHNOLOGY MAY BE ELIGIBLE FOR CONSIDERATION AS A CENTER MEMBER. FORM 990, PART VI, SECTION A, LINE 7A FOR EACH SECTION IN WHICH THE MEMBER PARTICIPATES, EACH MEMBER SHALL HAVE THE RIGHT TO VOTE ON THE ELECTION OF DIRECTORS FOR THE SECTION GOVERNING BOARD, BUT SHALL HAVE NO OTHER VOTING RIGHTS EXCEPT ON MATTERS BROUGHT TO THE MEMBERSHIP BY ANY SUCH GOVERNING BOARD OR THE ORGANIZATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 AND RELATED SCHEDULES ARE PREPARED BY THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS UNDER THE GUIDANCE OF THE CFO. THE CFO AND THE CONTROLLER THOROUGHLY REVIEW ALL CALCULATIONS AND SCHEDULES TO CONFIRM THEY REFLECT THE ACTUAL FINANCIAL RESULTS OF THE ORGANIZATION. THE COMPLETE FORM 990 IS THEN REVIEWED INTERNALLY BY THE CEO, COO, CFO AND CONTROLLER IN CONSULTATION WITH LEGAL COUNSEL AND, AS APPROPRIATE, FURTHER CONSULTATION WITH THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS. FINALLY, THE FORM 990 IS PROVIDED TO THE CHAIRMAN OF THE BOARD FOR REVIEW, QUESTIONS AND/OR COMMENTS, AND THEN SENT TO THE BIO EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW, QUESTIONS AND/OR COMMENTS AS WELL. ALL REVIEWS ARE COMPLETED BEFORE THE FORM IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BIO TAKES SEVERAL STEPS TO ADDRESS COMPLIANCE BY EMPLOYEES AND DIRECTORS WITH ITS CONFLICTS OF INTEREST POLICY. BIO TRAINS ALL NEW EMPLOYEES AND DIRECTORS ON VARIOUS ASPECTS OF BIO'S COMPLIANCE PROGRAM, INCLUDING CONFLICTS OF INTEREST, AND BIO'S WRITTEN CONFLICTS OF INTEREST POLICY REQUIRES ALL EMPLOYEES TO DISCLOSE ANY OUTSIDE PERSONAL BUSINESS INTERESTS TO THEIR SUPERVISOR. BIO'S GENERAL COUNSEL REGULARLY ADVISES BIO'S EXECUTIVES AND SUPERVISORS ON SUCH MATTERS. BIO ALSO CONTRACTS WITH AN INDEPENDENT ORGANIZATION TO PROVIDE EMPLOYEES AND OTHERS WITH THE ABILITY TO FILE ANONYMOUS REPORTS CONCERNING THE VIOLATION OF ANY LAWS OR BIO POLICIES, INCLUDING ALLEGATIONS OF POTENTIAL CONFLICTS OF INTEREST, AND BIO HAS A PROCESS IN PLACE TO FOLLOW UP ON ANY SUCH COMPLAINTS IN A TIMELY AND THOROUGH MANNER. FURTHER, BIO UNDERTAKES A QUESTIONNAIRE SENT TO EACH MEMBER OF ITS BOARD OF DIRECTORS SEEKING DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTERESTS THEY MAY HAVE, OR THEIR FAMILY MEMBERS MAY HAVE, ASSOCIATED WITH BUSINESSES OR ORGANIZATIONS THAT DO BUSINESS WITH BIO. POTENTIAL CONFLICTS ARE MONITORED AND REVIEWED AT THE MANAGEMENT AND SENIOR MANAGEMENT LEVEL OF THE ORGANIZATION, AND DEPENDING ON THE CONFLICT, DETERMINATIONS MAY BE MADE AT THE BOARD OR SENIOR MANAGEMENT LEVEL. A CONFLICT AT THE BOARD LEVEL WILL NORMALLY RESULT IN RECUSAL OF THE INDIVIDUAL FROM PARTICIPATION OR ACTIVITIES WITH RESPECT TO THE RELEVANT SUBJECT MATTER. AT THE STAFF LEVEL, THE APPLICABLE BIO SUPERVISOR IS INFORMED OF THE POTENTIAL CONFLICT AND IS REQUIRED TO TAKE ALL APPROPRIATE STEPS TO ENSURE THAT THE INDIVIDUAL DOES NOT PARTICIPATE IN, OR RECEIVE CONFIDENTIAL INFORMATION RELATING TO, ANY BIO ACTIVITY RELATED TO THE SUBJECT MATTER OF THE CONFLICT, UP TO AND INCLUDING, WHERE APPROPRIATE, TERMINATION OF SUCH EMPLOYEE. FORM 990, PART VI, SECTION B, LINE 15 IN 2011, THE EXECUTIVE AGREEMENT FOR THE PRESIDENT AND CEO OF BIO WAS RENEGOTIATED AND RENEWED, IN A PROCESS THAT WAS LED BY THE CHAIRMAN OF THE BOARD, IN CONSULTATION WITH EXTERNAL INDEPENDENT LEGAL AND COMPENSATION CONSULTANTS AND WITH THE FULL BOARD OF DIRECTORS, AND FINAL APPROVAL BY THE BIO EXECUTIVE COMMITTEE OF THE BOARD. IN 2011, THE BIO EXECUTIVE COMMITTEE ALSO EVALUATED THE PERFORMANCE OF THE BIO PRESIDENT AND CEO UNDER HIS PRIOR EXECUTIVE AGREEMENT, AND BASED ON THIS PERFORMANCE EVALUATION, DETERMINED THE APPROPRIATE AMOUNT FOR THE DISCRETIONARY COMPONENT OF HIS COMPENSATION FOR THAT YEAR. THE COMPENSATION HE RECEIVED IS DETAILED THROUGH THIS EXECUTIVE AGREEMENT. THE BIO EXECUTIVE COMMITTEE, WHICH IS COMPRISED OF INDEPENDENT BIO BOARD MEMBERS, LEADS AND UNDERTAKES THIS ANNUAL PROCESS. IN CARRYING OUT BOTH FUNCTIONS, THE MEMBERS OF THE EXECUTIVE COMMITTEE ARE ASSISTED AND COUNSELED, CONTEMPORANEOUSLY, BY BOTH INDEPENDENT OUTSIDE LEGAL COUNSEL WHO IS AN EXPERT IN THIS AREA OF THE LAW, AND AN INDEPENDENT OUTSIDE CONSULTANT THAT PROVIDED BENCHMARKING SERVICES AND INFORMATION ON EXECUTIVE COMPENSATION ISSUES. FORM 990, PART VI, SECTION B, LINE 15B: DECISIONS REGARDING THE COMPENSATION FOR OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION ARE NEGOTIATED INDIVIDUALLY AND ARE PERFORMANCE-BASED, IN ACCORDANCE WITH AN ANNUAL WRITTEN EVALUATION PROCESS THAT HAS BEEN ESTABLISHED FOR ALL EMPLOYEES OF THE ORGANIZATION. THE CHIEF OPERATING OFFICER LEADS AND UNDERTAKES THIS PROCESS, IN COORDINATION WITH THE PRESIDENT & CEO. AN INDEPENDENT CONSULTANT PROVIDES COMPARATIVE BENCHMARKING SERVICES FOR SENIOR MANAGEMENT POSITIONS, AND OTHER INFORMATION ON COMPENSATION ISSUES, TRENDS, POLICIES, AND BEST PRACTICES FOR USE BY THE ORGANIZATION. THE ORGANIZATION ALSO HAS AN ESTABLISHED COMPENSATION POLICY FOR ALL OF ITS EMPLOYEES, WHICH SETS FORTH THE GENERAL PARAMETERS GOVERNING BIO'S COMPENSATION PRACTICES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -1,204,082. CBI REVENUE 31,741. CBI LOBBYING FUND REVENUE 442,576. FOOD & AG INITIATIVES REVENUE 128,507. FOOD & AG INITIATIVES EXPENSES -132,791. CBI LOBBYING FUND EXPENSE -455,805. TOTAL TO FORM 990, PART XI, LINE 5: -1,189,854.